Scancell buddies up with 'new immuno-oncology powerhouse'

9 January 2018

UK-based oncology specialist Scancell Holdings (LSE: SCLP) has announced a collaboration with Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.

The collaboration will focus on the potential development of innovative, T-cell receptor based therapeutics for the treatment of cancer and combines Scancell’s Moditope immunotherapy platform and BioNTech’s technology for high-throughput cloning and characterization of naturally selected T-cell receptors.

"Our Moditope platform has shown unprecedented anti-tumor effects can be delivered without the need for checkpoint inhibition. We believe that this, combined with BioNTech’s engineered T-cells specific to Moditope epitopes, could have great potential"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK